tbuckley/cabot-search huggingface dataset:
AB0994 Impact on the adherence and persistence of denosumab vs weekly bisphosphonate in health-related quality of life in postmenopausal osteoporosis
Authors: G. Carlino, R. Cinzia, R. Maggio
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Long term adherence and persistence in patients undergoing treatment for postmenopausal osteoporosis remains poor despite the proven efficacy of the therapy. <h3>Objectives</h3> In this study, we evaluated whether greater adherence and persistence in treatment can lead to an improvement in the quality of life. <h3>Methods</h3> A cohort of 268 patients, all women, in postmenopausal osteoporosis divided into two groups was evaluated: "DEN Group" (DEN) in treatment with denosumab (n=131) and "BIS Group" (BIS) in treatment with bisphosphonates (n=137). Table 1 shows demographic and clinical data. Patients were followed for 3 years with baseline, 6 month, 18 month, and 36 month evaluation. The evaluation criteria were the persistence in therapy and the self-related treatment compliance, as well as the quality of life assessed with the 41-item Quality of Life questionnaire for osteoporosis (QUALEFFO-41) performed at baseline, at 18 and at 36 months. <h3>Results</h3> Table 2 shows the percentage of patients who abandoned treatment at different times with a statistical significance towards both 18 and 36 months. In the BIS the main reason for abandonment were the adverse events (gastrointestinal, dental interventions, etc.), in the DEN the abandonment was due to drop-out. [In BIS, the most frequent reason for non-compliance with therapy was oversight, and most patients who continued treatment always used the drugs regularly on the recommended days and dosages.] In the period of time considered the majority of patients both BIS and DEN said they were satisfied with the treatment and wanted to continue it. The QUALEFFO scores (Fig 1) of patients from the baseline visit were significantly improved in the 36 month visit (BIS 79.6±25.4 vs 65.4±14.6; DEN 80.2±18.5 vs 55.6*±16.4 (*p&lt;0.001); the difference was not significant between BIS and DEN groups at both baseline visit and 36 month visit, but in the DEN group there was significance between baseline and 36 month visit. OC=Osteocalcin, CTX=C terminal telopeptide, PTH=parathyroid hormone, 25OHD=25 hydroxyvitamin D; Abstract AB0994 – Table 2 Percentage of patients who abandoned. <h3>Conclusions</h3> In conclusion, the observation, although numerically limited, notes that the use of denosumab in patients with postmenopausal osteoporosis leads to a greater persistence in treatment and a statistically significant adherence to therapy, which allows to obtain the maximum therapeutic effect of the therapy, also determining in 36 months of treatment an improvement in the quality of life, which is not achieved in subjects treated with bisphosphonates. <h3>Disclosure of Interest</h3> None declared
AB1052 Comparison of several biomarkers (MMP-2, MMP-9 AND ITS INHIBITOR TIMP-1, CTX-II, CALPROTECTIN AND COMP) in the synovial fluid and serum of patients with and without septic arthritis
Authors: M. Couderc, C. Peyrode, B. Pereira, E. Miot-Noirault, S. Mathieu, M. Soubrier, J.-J. Dubost
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Diagnosing septic arthritis (SA) is an emergency, and for a diagnosis to be made a microorganism must be found in the synovial fluid or blood culture. Besides direct bacteriological examination, which is positive in only 25% to 50% of cases, no laboratory examination can differentiate SA from other forms of arthritis. <h3>Objectives</h3> To assessed the performances of several serum and synovial biomarkers (matrix metalloproetinase [MMP]−2, MMP-9, the metalloproteinase inhibitor [TIMP]−1, cartilage oligomeric matrix protein [COMP], C-terminal telopeptide of type II collagen [CTX-II], and calprotectin [CALP]) for discriminating between septic and non-SA in a population of patients with suspected SA. <h3>Methods</h3> Using the ELISA technique, a number of potential biomarkers (MMP-2, MMP-9, TIMP-1, COMP, CTX-II, and CALP) were measured in the synovial fluid and serum of 39 patients with suspected SA (of whom 21 had SA and 18 non-SA). (. The levels of the various markers were compared on univariate and then multivariate analysis using logistic regression. <h3>Results</h3> The two groups were similar in terms of age, gender, history of diabetes and type of joint affected. SA patients had higher whole blood white blood cell counts (p=0.03) but similar C-reactive protein levels. Synovial fluid was more frequently turbid in septic cases than in non-septic ones. Serum TIMP-1 (p=0.003), synovial MMP-9 (p=0.002), serum (p=0.03) and synovial CTX-II (p=0.004), and serum (p=0.04) and synovial CALP (p=0.03) were significantly higher in the septic group than in the non-septic group. The AUCs for diagnosing SA of synovial MMP-9, serum TIMP-1, synovial CTX-II, and serum and synovial CALP were, respectively, 0.84, 0.79, 0.81, 0.7 and 0.72. A combination of serum TIMP-1 and synovial CTX-II led to 75% sensitivity and 94% specificity for diagnosing SA (AUC 0.89) and correctly classified patients in 86% of cases. Serum TIMP-1 and synovial CTX-II did not correlate with each other (r=0.1) and did not correlate with C-reactive protein (r=0.4 and r=0.25, respectively) or synovial white blood count (r=−0.04 and r=0.27, respectively). <h3>Conclusions</h3> The combination of two laboratory measurements, serum TIMP-1 and synovial CTX-II, may make it possible to differentiate SA from other forms of arthritis in 86% of cases. These results need to be confirmed in larger samples of patients. <h3>Disclosure of Interest</h3> None declared
Dark skin phototype is associated with more severe ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis
Authors: D. Thorel, A. Delcampe, S. Ingen‐Housz‐Oro, C. Hajj, E. Gabison, O. Chosidow, P. Wolkenstein, G. Royer, K. Ezzedine, M. Muraine, J. Gueudry
Journal: British Journal of Dermatology (2019)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not.The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis
THU0050 Hypoxia induces production of citrullinated proteins in human fibroblast-like synoviocytes through regulating hif1Α
Authors: R. Yu, C. Li, L. Sun, L. Jian, Z. Ma, J. Zhao, X. Liu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Hypoxia is a prominent microenvironment feature in a range of disorders including cancer, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel disease (IBD), infection and obesity. Hypoxia promotes biological functions of fibroblast-like synoviocytes via regulating hypoxia-inducible factor 1α (HIF1α). Dysregulated protein citrullination in RA drives the production of antibodies to citrullinated proteins, a highly specific biomarker of RA. However, the mechanisms promoting citrullination in RA are not yet fully elucidated. <h3>Objectives</h3> In the present study, we investigated whether pathophysiological hypoxia as found in the rheumatoid synovium modulates the citrullination in human fibroblast-like synoviocytes (HFLS). <h3>Methods</h3> HFLS were incubated in a hypoxic chamber (5% CO<sub>2</sub> and 1% O<sub>2</sub>, balanced with N<sub>2</sub> as indicated) or in a normal incubator containing 5% CO<sub>2</sub> and approximately 20% O<sub>2</sub>. The realtime quantitative PCR and western blotting were used to detect the expression of peptidylarginine deiminase 2, peptidylarginine deiminase 4 and citrullinated proteins. HFLS were transfected with HIF1α siRNA to block the HIF1α pathway. <h3>Results</h3> In the present study, we found that peptidylarginine deiminase 2 (PAD2) and citrullinated proteins were increased in HFLS after exposed to hypoxia. Moreover, knocking down HIF1α by hif1α siRNA ameliorated the expression of PAD2 and citrullinated proteins. <h3>Conclusions</h3> Collectively, the present study provide a new mechanism involved in generating citrullinated proteins: hypoxia promote citrullination and PAD production in HFLS. Concurrently, we also proposed a novel hypoxia involved mechanism in RA pathogenesis. The present study deepens our understanding of the role of hypoxia in the pathogenesis of RA and provides potential therapeutic strategy for RA. <h3>Acknowledgements</h3> We thank Jiansheng Huang for providing language help and revising the manuscript. <h3>Disclosure of Interest</h3> None declared
AB1248 Vaccination rate in patients with rheumatic diseases: a cross-sectional study in mexican patients
Authors: J.P. Carrizales-Luna, D. Galarza-Delgado, J. Esquivel-Valerio, G. Serna-Peña, L. Ramírez-Monterrubio, L. Lozano-Plata, I. Hernández-Galarza, T. Gracia-Arechiga
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with rheumatic diseases have an increased risk of infections, which can be prevented with vaccination schemes. The vaccination rate in rheumatic patients is low in Mexico (17%–25%), mainly because of the lack of physician recommendation. Vaccination strategies have been shown to improve adherence to the application. <h3>Objectives</h3> The objectives of the study was to determine the vaccination rate in patients with rheumatic diseases and the main reasons of failed vaccination. <h3>Methods</h3> We questioned 84 patients from the rheumatology clinic of the Univesitary Hospital "José E. González", Mexico, from June to July 2017. The vaccination status and the reasons for failed vaccination were recorded. <h3>Results</h3> The majority of patients were women (89.3%), average age 50 years (17–81 years). Most of the patients had rheumatoid arthritis (45.3%), followed by other autoimmune diseases (27.4%) and non-autoimmune diseases (27.4%). The highest rates of vaccination were for tetanus-diphtheria (44%), influenza (39.3%) and pneumococcus (31%). They were lower for hepatitis B virus (9.8%), human papilloma virus (4.8%), hepatitis A virus (2.4%) and herpes zoster virus (0%). The main reason for failed vaccination was the lack of indication from the physician (34.5%). If indicated, 89.3% of the patients would accept to be vaccinated. <h3>Conclusions</h3> We found a low vaccination rate in the rheumatology clinic. We found an insufficient promotion and indication of vaccination by the rheumatology staff. Constant fomentation and updated knowledge about vaccination recommendations in autoinmune diseases is necessary for the prevention of infections and to improve the comprehensive care of patients with rheumatic diseases. <h3>References</h3> [1] Garg S. ACR Abstracts. 2016. [2] Kostantinos T &amp; Vassilopoulus D. Best Practice &amp; Research Clinical Rheumatology xxx (2016) 1e18. [3] Black S, et al. ACR Abstracts. 2011. [4] Bühler S, et al. Swiss Med Wkly. 2015;145: w14159 <h3>Disclosure of Interest</h3> None declared
THU0334 Patterns of aspirin use in sle pregnancies within a multinational inception cohort and relationship to preeclampsia risk factors
Authors: A. Mendel, S. Bernatsky, E. Vinet
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Aspirin reduces the risk of preeclampsia in pregnancies at high risk, and is recommended in pregnant women with ≥1 risk factors for preeclampsia, including systemic lupus erythematosus (SLE). <h3>Objectives</h3> To assess the prevalence of aspirin use in SLE pregnancies within a multinational inception cohort and compare aspirin use among those with and without additional preeclampsia risk factors. <h3>Methods</h3> Premenopausal women aged 18–45 enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) Registry (2000–2017) within 15 months of SLE onset were evaluated with yearly visits to update co-morbidities, pregnancy status, and medications. Study visits with a current pregnancy were assessed for aspirin use and preeclampsia risk factors. Aspirin use was compared over time and among those with and without traditional risk factors for preeclampsia (i.e. hypertension, renal disease, diabetes, nulliparity, BMI≥35, age &gt;40), as well as known disease-specific risk factors (i.e. antiphospholipid antibodies [+aPL], nephritis). <h3>Results</h3> We identified 297 women who had 479 pregnancies over the study period. Mean age during pregnancy was 31 (SD 4.9) years and 30% were nulliparous. Half of the pregnancies experienced ≥1 traditional preeclampsia risk factors in addition to SLE, while a third had +aPL. We observed aspirin use in 121/475 25% of pregnancies (95% CI 22,29) versus 22% (95%CI 19,25) of visits before and after pregnancy among the same women. Aspirin use was similar among pregnancies with and without ≥1 traditional risk factor for preeclampsia [25% (95%CI 20,31) versus 26% (95%CI 21,32)], while we observed a higher prevalence of aspirin use in those with +aPL (38%, 95% CI 24,55) versus those without (23%, 95% CI 15,34). There was a significant difference in aspirin use based on maternal race/ethnicity, with 67/205 (33%, 95% CI 26,39) aspirin use in Caucasians versus 9/88 (10%, 95% CI 5,18) for black women. Prevalence of aspirin use in pregnancy varied across regions (12%&gt;37%), and did not increase over time. <h3>Conclusions</h3> In this cohort including 479 SLE pregnancies, most pregnant women were not on aspirin and half had preeclampsia risk factors in addition to SLE. It is possible that aspirin was introduced at/or following the study visit when the pregnancy was documented, highlighting the importance of the treating rheumatologist in reviewing aspirin use and initiating it in pregnant SLE women. Our findings suggest black SLE women as a potentially vulnerable group during pregnancy, having the lowest prevalence of aspirin use. <h3>Disclosure of Interest</h3> None declared
THU0596 Measurement of serum calprotectin mrp8/14 in paediatric patients diagnosed with juvenile idiopathic arthritis and autoinflammatory diseases
Authors: S. Murias, C. Udaondo, R.M. Alcobendas, A. Remesal, D. Pascual-Salcedo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There is evidence of the correlation between serum levels of calprotectin MRP8/14 and disease activity in Juvenile Idiopathic Arthritis (JIA), but the same correlation with other rheumatic diseases in children such as autoinflammatory diseases has not been studied as much. <h3>Objectives</h3> To analyse calprotectin MRP8/14 in serum of patients with juvenile idiopathic arthritis (JIA) and various autoinflammatory diseases with different degrees of activity. To check if there is a correlation between serum MRP8/14 and disease activity. <h3>Methods</h3> Study in two phases:<b> 1)</b> Initial, transversal, in JIA and/or autoinflammatory disease patients, determining serum MRP8/14 (by ELISA test) and collecting clinical data: number of active joints, Visual Analogue Scale parents/patients (VASp), VAS physician (VASph); and analytical: C-Reactive Protein (CPR) and white cells blood count (WBC) (among others).<b> 2)</b> Second prospective phase, repeating the same analysis 3–6 months later. Disease activity was assessed by Juvenile Arthritis Disease Activity Score (JADAS) in AIJ; and by VASp, VASph and CRP in autoinflammatory diseases. <h3>Results</h3> The sample included 90 patients (25 males) between the ages of 1 and 21 years (median 11.1); 61 diagnosed with JIA (excluding systemic category), and 29 with different autoinflammatory diseases (including systemic JIA). 69 patients (20 males, with median age 11.2, 48 AIJ, 21 autoinflammatory) participated in the prospective phase. The main results are shown in table 1. MRP=myeloid related proteins. JADAS=Juvenile arthritis disease activity score. ACJ=active joints count. VASm=visual analogue scale–physician. VASp=visual analogue scale-parents/patient. CRP=C reactive Protein. <h3>Conclusions</h3> In patients with non-systemic JIA, a positive correlation was found between serum MRP8/14 and JADAS, VASph, VASp, CRP, WBC, neutrophilia and (inversely) haemoglobin. In autoinflammatory diseases positive correlation has been found with VASm, CRP, leukocytosis, neutrophilia, thrombocytosis and (inversely) haemoglobin. MRP8/14 seems to behave as a marker of activity in both JIA and autoinflammatory diseases, although with a stronger association in the latter. <h3>Disclosure of Interest</h3> None declared
Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
Authors: Aneel Paulus, Prachi Jani, Salman Ahmed, Sonikpreet Aulakh, Alak Manna, Neeraj Kumar Singh, Mohammed Sauban, Zakir Husain, Ansu Kumar, Pallavi Kumari, Anuj Tyagi, Taimur Sher, Rami Manochakian, Vivek Roy, Taher Abbasi, Shireen Vali, Asher A. Chanan-Khan, Sikander Ailawadhi
Journal: Blood (2018)
AB0359 Clinic profile of patients with rheumatoid arthritis and pulmonary affection in a cohort from a university hospital
Authors: I. Casafont Solé, Á. Prior-Español, S. Holgado, J. Roca, L. Mateo, Y. García-Mira, J. Camins, L. Gifre, A. Riveros, M. Martínez-Morillo, M. Aparicio, A. Olivé
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pulmonary affection is a serious complication in Rheumatoid Arthritis (RA) with an important impact on mortality and morbidity. <h3>Objectives</h3> To describe the clinical and radiographic characteristics of patients with RA in our centre, and specifically from those with interstitial lung disease (ILD). <h3>Methods</h3> Retrospective analysis of patients with RA and pulmonary affection from a University Hospital with a referral area of 85.000 inhabitants. Clinical, laboratory, imaging and pulmonary function test (PFT) data was recorded. <h3>Results</h3> Data from 85 patients, 37 (43.5%) male and 48 (56.5%) female, were recorded. The mean time from RA diagnosis to pulmonary disease was 9.2 years, with mainly erosive (58.8%) and seropostive (84.7% were positive rheumatoid factor (RF) and 84.2% anti-citrullinated protein antibodies (ACPA)) disease. The 56.5% of the patients were smokers or ex-smokers. PFT results were documented in 75.3% of the patients: diffusing capacity for carbon monoxide (DCLO) baseline values were over 60% in a 38.8% of cases and forced vital capacity (FVC) baseline values were over 50% in a 69.4% of patients. The most frequent High Resolution CT scan pattern was the presence of bronchiectasis (64.7%), followed by ILD (31.8%) and, specifically, the Usual Interstitial Pneumonia pattern (UIP, 66.6%); lung infections (25.8%), rheumatoid lung nodules (22.4%), pleural effusion (15.3%), lung tumours (9.4%) and bronchiolitis (5.8%). The presence of extra articular manifestations as rheumatoid nodules (27%), epieschleritis (2.3%) and vasculitis (9.4%) was registered. The coexistence of Chronic Obstructive Pulmonary Disease (COPD) was recorded too (24.7%). Related to treatment, 84.7% of patients had received Methotrexate and in a 40% of cases, at least one biological disease-modifying antirheumatic drug had been administrated. Though the causes were not registered, a 25.9% of deaths were documented. In parallel we did a subanalysis of ILD related to RA cases, summarised in table 1 (n=27): <h3>Conclusions</h3> Bronchiectasis is the most common pulmonary manifestation of RA patients in our area. The most frequent clinical profile is a non-smoker woman with seropositive disease. ILD affects approximately one third of RA patients in our area and is an underdiagnosed entity. We consider that it is necessary to establish a screening program to diagnose and treat it early. <h3>Disclosure of Interest</h3> None declared
FRI0706-HPR Values underlying disease-modifying antirheumatic drug preferences of patients with rheumatoid arthritis
Authors: E. Mathijssen, J. Vriezekolk, B. van den Bemt
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of treatment in rheumatoid arthritis (RA). Each DMARD has its own characteristics (e.g. onset of action, route of administration and dosing frequency). Treatment decisions should ideally be made through a shared decision making (SDM) process between clinicians and patients, taking account of patient preferences (1,2). This requires an understanding of patient preferences. A number of studies have explored DMARD preferences of patients with RA (3). However, insight into values underlying DMARD preferences that may drive patients' treatment decisions is still lacking. Such information is relevant for clinicians in order to better understand patient preferences. Ultimately, this will facilitate the SDM process. <h3>Objectives:</h3> To provide insight into values underlying DMARD preferences of patients with RA. <h3>Methods:</h3> A secondary analysis of transcripts from three focus groups in patients with RA. Two researchers independently analysed the transcripts, using thematic analysis with an inductive approach. <h3>Results:</h3> Twenty-three patients participated in the focus groups. They had a median age of 62 years (range: 36–78 years), 87% were female and the median disease duration was 11 years (range: 2–42 years). Three values were identified: certainty, independency and safety. Certainty: patients wanted to be certain that the DMARD would work for them. DMARD characteristics that represented this value were onset of action and efficacy. Independency: a DMARD that could easily be fitted into patients' everyday lives was considered important. Route of administration, dosing frequency, location of administration and storage conditions were DMARD characteristics that represented this value. Safety: patients wanted to prevent health damage related to their DMARD use. DMARD characteristics that represented this value were chance of side effects, severity of side effects and consequence of long term use. <h3>Conclusions:</h3> Certainty, independency and safety are important values to patients with RA. These values underlie DMARD preferences that may drive patients' treatment decisions. This deserves attention in the SDM process. <h3>References</h3> 1. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol2016;68:1–26. 2. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–77. 3. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence2009;3:335–44. <h3>Disclosure of Interest:</h3> None declared